MEDINET Co., Ltd.

Tokyo Stock Exchange 2370.T

MEDINET Co., Ltd. Cash and Short-Term Investments for the year ending September 30, 2024: USD 32.36 M

MEDINET Co., Ltd. Cash and Short-Term Investments is USD 32.36 M for the year ending September 30, 2024, a 9.99% change year over year. Cash and short-term investments are the sum of cash and short-term investments, representing the company's liquid assets.

MEDINET Co., Ltd. Cash and Short-Term Investments for the year ending September 30, 2023 was USD 29.42 M, a -5.33% change year over year.
MEDINET Co., Ltd. Cash and Short-Term Investments for the year ending September 30, 2022 was USD 31.08 M, a -15.55% change year over year.
MEDINET Co., Ltd. Cash and Short-Term Investments for the year ending September 30, 2021 was USD 36.80 M, a 6.49% change year over year.
MEDINET Co., Ltd. Cash and Short-Term Investments for the year ending September 30, 2020 was USD 34.55 M, a 166.12% change year over year.

Key data

Date	Cash and Short-Term Investments	Receivables	Inventory	Goodwill

Tokyo Stock Exchange: 2370.T

MEDINET Co., Ltd.

CEO	Kanenao Kubushiro
IPO Date	Oct. 8, 2003
Location	Japan
Headquarters	TRC Center Building
Employees	92
Sector	Health Care
Industries Biotechnology Pharmaceuticals

Description

MEDINET Co., Ltd. operates as a contract development and manufacturing organization that provides regenerative medicine and cell therapy solutions in Japan. Its solutions include technical know-how, facilities, systems, materials, professional cell-engineers, and other requirements to conduct immuno-cell therapy. The company also manufactures regenerative medical/investigational and specified cell products. In addition, its value chain solutions include personnel training, facility and equipment design, facility operations and management, preparation of standard operating procedures, logistics network, information system, purchasing and production management, quality management system, quality control and assurance, and technology transfer and process development solutions. Further, the company supports medical institutions, research institutions, and biopharmaceutical companies to conduct immuno-cell therapy. MEDINET Co., Ltd. was incorporated in 1995 and is headquartered in Tokyo, Japan.

Key trends

Past 5 years